Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy with carboplatin, etoposide and epirubicin

Nyman, C R
August 1992
Thorax;Aug1992, Vol. 47 Issue 8, p668
Academic Journal
No abstract available.


Related Articles

  • Can Carboplatin replace Cisplatin in small cell lung cancer? Noronha, V. // Indian Journal of Cancer;Oct-Dec2011, Vol. 48 Issue 4, p452 

    An introduction is presented which discusses topics within the issue including notable activity of Cisplatin and Etoposide combination in patients with small cell lung cancer, effectiveness of the combination of Carboplatin and Etoposide, and evidence supporting the use of Carboplatin in patients.

  • Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases. Mizugaki, Hidenori; Fujiwara, Yutaka; Yamamoto, Noboru; Yagishita, Shigehiro; Kitazono, Satoru; Tanaka, Ayako; Horinouchi, Hidehito; Kanda, Shintaro; Nokihara, Hiroshi; Tsuta, Koji; Asamura, Hisao; Tamura, Tomohide // Japanese Journal of Clinical Oncology;Sep2014, Vol. 44 Issue 9, p835 

    Objective Several clinical studies have demonstrated the efficacy and safety of adjuvant chemotherapy in patients with completely resected small cell lung cancer for a selected limited stage. However, it is unclear whether adjuvant chemotherapy is feasible in clinical practice. The objective of...

  • Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer. Reck, Martin; von Pawel, Joachim; Macha, Hans-Nicolas; Kaukel, Eckhard; Deppermann, Karl-Matthias; Bonnet, Reiner; Ulm, Kurt; Hessler, Sybill; Gatzemeier, Ulrich // JNCI: Journal of the National Cancer Institute;8/06/2003, Vol. 95 Issue 15, p1118 

    Cites the results of a randomized phase III trial from 1998 to 1999 comparing the efficacy of carboplatin, etoposide and paclitaxel and of vincristine, etoposide and carboplatin in treating small-cell lung cancer. Patient eligibility; Treatment protocol; Treatment evaluations and statistical...

  • Thalidomide in Small Cell Lung Cancer: Wrong Drug or Wrong Disease? Rüegg, Curzio; Peters, Solange // JNCI: Journal of the National Cancer Institute;8/5/2009, Vol. 101 Issue 15, p1034 

    The authors discuss a placebo-controlled trial conducted by Lee and colleagues in small cell lung cancer (SCLC) combining thalidomide with carboplatin and etoposide chemotherapy. They discuss Pujol and collegues' phase III study in 2008 in which thalidomide was combined with cisplatin,...

  • Re: "A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small-Cell Lung Cancer: A Randomized Trial". Bregni, Marco; Pedrazzoli, Paolo; Pampallona, Sandro; Leyvraz, Serge // JNCI: Journal of the National Cancer Institute;1/7/2009, Vol. 101 Issue 1, p67 

    A letter to the editor is presented in response to the article "A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small-Cell Lung Cancer: A Randomized Trial" that was published in a previous issue.

  • Carboplatin/etoposide phosphate.  // Reactions Weekly;Sep2015, Vol. 1570 Issue 1, p40 

    The article describes the case of neutropenia that developed in a 21-year-old woman during treatment with etoposide phosphate and carboplatin for small-cell lung cancer.

  • Telik initiates first triplet combination trial with Telcyta.  // PharmaWatch: Cancer;August 2004, Vol. 3 Issue 8, p10 

    Telik Inc. has revealed the initiation of a new phase II clinical trial in which Telcyta will be evaluated in combination with carboplatin and paclitaxel in the front-line treatment of Stage IIIb or IV non-small cell lung cancer. The trial is expected to enroll approximately 50 non-small cell...

  • Carboplatin/etoposide.  // Reactions Weekly;1/5/2013, Issue 1433, p13 

    The article describes the case of a 74-year-old man who developed febrile neutropenia, relapse of pulmonary mucormycosis and subsequently died while receiving treatment with carboplatin and etoposide for stage 3B small cell lung cancer.

  • Chemotherapy Alone or Chemotherapy with Chest Radiation Therapy in Limited Stage Small Cell Lung Cancer. Bunn Jr., Paul A.; Lichter, Allen S.; Makuch, Robert W.; Cohen, Martin H.; Veach, Stephen R.; Matthews, Mary J.; Anderson, Anita Johnston; Edison, Margaret; Glatstein, Eli; Minna, John D.; Ihde, Daniel C. // Annals of Internal Medicine;May87, Vol. 106 Issue 5, p655 

    Discusses a study on the effect of concurrent chest radiation therapy on response rate, recurrence, and treatment toxicity among patients with limited stage small cell lung cancer who are receiving combination chemotherapy. Characteristics and treatment responses of patients treated for limited...

  • Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer. Dean, Emma J.; Cummings, Jeff; Roulston, Anne; Berger, Mark; Ranson, Malcolm; Blackhall, Fiona; Dive, Caroline // Neoplasia;Apr2011, Vol. 13 Issue 4, p339 

    Small cell lung cancer (SCLC) is an aggressive disease in which, after initial sensitivity to platinum/etoposide chemotherapy, patients frequently relapse with drug-resistant disease. Deregulation of the Bcl-2 pathway is implicated in the pathogenesis of SCLC, and early phase studies of Bcl-2...


Read the Article


Sign out of this library

Other Topics